title: Complete Remission of Squamous Cell Carcinoma After Treatment With Panitumumab in a Patient With Cetuximab-Induced Anaphylaxis.
authors.affiliation: Dermatology Department, CHU de Bordeaux, University of Bordeaux, Bordeaux, France.
authors.forename: Aurélie
authors.initials: A
authors.lastname: Marti
authors.affiliation: Dermatology Department, CHU de Bordeaux, University of Bordeaux, Bordeaux, France.
authors.forename: Antoine
authors.initials: A
authors.lastname: Fauconneau
authors.affiliation: Radiotherapy Department, CHU de Bordeaux, Hôpital Haut Lévêque, Bordeaux France.
authors.forename: Nora
authors.initials: N
authors.lastname: Ouhabrache
authors.affiliation: Dermatology Department, CHU de Bordeaux, University of Bordeaux, Bordeaux, France.
authors.forename: Marie
authors.initials: M
authors.lastname: Beylot-Barry
authors.affiliation: Dermatology Department, CHU de Bordeaux, University of Bordeaux, Bordeaux, France.
authors.forename: Anne
authors.initials: A
authors.lastname: Pham-Ledard
mesh_terms: D000369:Aged, 80 and over; D000707:Anaphylaxis / Q000139:chemically induced*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D000068818:Cetuximab / Q000008:administration & dosage* / Q000627:therapeutic use; D057915:Drug Substitution; D006801:Humans; D008297:Male; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D000077544:Panitumumab; D012074:Remission Induction; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D000077544:Panitumumab; D000068818:Cetuximab